厄贝沙坦联合螺内酯对原发性高血压患者左室构型的影响  

Effect of Irbesartan Combined with Spironolactone on Left Ventricular Configuration in Primary Hypertension Patients

作　　者：霍刚[1] 林燕飞[1] 苏华科[1] 李文军[1] 田嘉欣[1] 赵生家[1] 

机构地区：[1]解放军第253医院心肾内科,呼和浩特010051

出　　处：《中国药房》2014年第28期2628-2630,共3页China Pharmacy

摘　　要：目的:观察厄贝沙坦联合螺内酯对原发性高血压患者左室构型的影响。方法:将符合标准的106例原发性高血压患者按随机数字表法分为对照组(50例)和干预组(56例)。对照组患者给予二氢吡啶类钙拮抗药、β受体阻滞药、噻嗪类利尿药等常规治疗;干预组患者在对照组治疗的基础上给予厄贝沙坦分散片首次剂量75 mg,口服,bid,两周后视病情改善情况剂量增加至150mg,口服,bid,同时给予螺内酯10 mg,口服,bid。两组患者疗程均为24周。观察两组患者治疗前后收缩压(SBP)、舒张压(DBP)、左室舒张末期内径(LVEDD)、舒张末期室间隔厚度(IVSTd)、左室后壁厚度(LVPWTd)、左室质量指数(LVMI)及不良反应发生情况。结果:治疗前两组患者SBP、DBP、LVEDD、IVSTd、LVPWTd、LVMI比较,差异无统计学意义(P>0.05)。治疗后两组患者SBP、DBP均显著低于同组治疗前,差异有统计学意义(P<0.05);但两组间比较,差异无统计学意义(P>0.05);治疗后干预组患者LVEDD、IVSTd、LVPWTd、LVMI均显著低于同组治疗前,对照组患者仅LVEDD显著低于同组治疗前,差异有统计学意义(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:厄贝沙坦联合螺内酯可有效减轻左室肥厚,逆转原发性高血压所致的左室重构。OBJECTIVE：To investigate the effect of irbesartan combined with spironolactone on left ventricular configuration in primary hypertension patients. METHODS：106 patients with primary hypertension were randomly divided into intervention group（58 cases）and control group（50 cases）. Control group was given conventional treatment of Fluazifop calcium antagonist,β-receptor blockers and Thiazine diuretic. Intervention group was given Irbesartan dispersible tablet orally with initial dose of 75 mg,twice a day,increasing to 150 mg,twice a day,according to the improvement of disease condition,and spirolactone 10 mg orally. Treatment course of 2 groups lasted for 24 weeks. SBP,DBP,LVEDD,end-diastolic ventricular septal thickness（IVSTd）,end-diastolic left ventricular posterior wall thickness（LVPWTd）and ADR were observed in 2 groups before and after treatment.RESULTS：SBP,DBP,LVEDD,IVSTd,LVPWTd and LVMI of 2 groups had no statistical significance before treatment（P〉0.05）. SBP and DBP of 2 groups after treatment were significantly lower than before;there was statistical significance（P〈0.05）.However,those had no statistical significance between 2 groups（P〉0.05）. LVEDD,IVSTd,LVPWTd and LVMI of intervention group after treatment were significantly lower than before;LVEDD of control group was significantly lower than before;there was statistical significance（P〈0.05）. CONCLUSIONS：Irbesartan combined with spironolactone can effectively reduce the left ventricular hypertrophy,and reverse left ventricular configuration caused by primary hypertension.

关 键 词：厄贝沙坦 螺内酯 左室构型 原发性高血压 

分 类 号：R544.1[医药卫生—心血管疾病]